Living donor liver transplantation for hepatocellular carcinoma in Indian patients-Is the scenario different?

Abstract

Living donor liver transplant (LDLT) for hepatocellular carcinoma (HCC) has been controversial in terms of selection and outcome. We share our experience of LDLT for HCC in Indian patients. Retrospective analysis of patients undergoing LDLT for HCC discovered either preoperatively or incidentally on explant pathology was done. Preoperative characteristics and explant histopathology findings were recorded. Overall, recurrence-free survival and factors predicting recurrence were analyzed. Six hundred and eleven LDLT were performed between June 2011 and October 2019. HCC constituted 6.5% (n = 53) of transplant activity. Forty had preoperative diagnosis, while 13 were detected incidentally. The median model for end-stage liver disease (MELD) score was 18 for patients with HCC. Only in 10 patients (19%), HCC was the primary indication for liver transplant (LT), and the rest had undergone transplant for progressive decompensation. Thirty-two patients were within up-to-7, while 21 were outside up-to-7 criteria. Overall 5-year survival was 85.4% and recurrence-free survival was 83.3% after a median follow-up of 35months (13-59). This was similar to LDLT for other indications (81.2% at 5years). Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score was best able to predict recurrence (p = 0.03) with odds ratio of 6.8. Patients with HCC in India present late for liver transplant. Most patients have some form of decompensation before they undergo LT. In selected patients, overall survival was comparable with other indications for LDLT with acceptable recurrence rates. RETREAT score was best to predict recurrence.